Why Cleanroom Design Matters in Aseptic Manufacturing
Effective cleanroom design sits at the very heart of safe aseptic manufacturing. For pharmaceutical products that cannot be terminally sterilised, production must take place within cleanrooms of class A or ISO 5, where regulatory limits on living and non-living particles are at their strictest. Lower-risk products, such as oral dosage forms, can tolerate lower cleanroom classes with correspondingly relaxed particulate and microbiological requirements. Good cleanroom design, therefore, begins with a clear understanding of product risk and the regulatory classification that flows from it.
Cleanroom Design and the Sources of Contamination
Contamination can enter a sterile product from several directions: personnel, the surrounding environment (air, surfaces and water), raw materials, auxiliary materials and the manufacturing process itself. A well-conceived cleanroom design accounts for each of these pathways, but design alone is not enough. An environmental monitoring programme must be established and documented to confirm that the cleanroom and its air handling units continue to deliver the cleanliness levels they were designed to achieve, and to flag any excursions that could put product quality at risk.
Regulatory Expectations Shaping Cleanroom Design
Annex 1 of the EU GMP guidelines sets out detailed expectations here. Grade A areas should be monitored continuously for particles of 0.5 µm and 5 µm, using a sample flow rate of at least 28 litres per minute, so that interventions, transient events and any deterioration in system performance are properly captured. Viable particle monitoring should likewise be frequent, drawing on a combination of settle plates, volumetric air sampling, and glove, gown and surface sampling, with surfaces checked at the end of each operation.
Air and Surface Sampling Within Cleanroom Design
Two broad approaches exist for assessing microbial counts in air. Passive air sampling, using settle plates exposed for up to four hours, is a simple, qualitative method well suited to locations where plates can be left undisturbed. Automatic settle plate changers now allow this to continue uninterrupted without operator intervention. Active air sampling, by contrast, draws a defined air volume — typically 1,000 litres — through the cleanroom, giving a quantitative germ count per volume measured. Surface contamination is generally assessed using contact plates, with swabs reserved for areas that are awkward to reach or too small for a contact plate.
Monitoring Non-Viable Particles in Cleanroom Design
Non-viable particles are tracked using particle counters that draw in air at a minimum of 28 litres per minute, reporting figures for particles above 5 µm and 0.5 µm. Manufacturers can implement these requirements conventionally, through settle plates paired with timed active air sampling, or through more advanced active samplers that operate at lower flow rates to achieve continuous coverage.
The Future-Oriented Approach to Cleanroom Design
A more forward-looking option is gaining momentum: rapid microbiological methods built around biofluorescent particle counters. These devices use laser-based detection to identify particles of biological origin in real time, reporting results as autofluorescent units rather than the traditional colony-forming units that microbiologists have relied on for well over a century. A single device can simultaneously capture total particle counts, viable particle counts and conventional CFU data from the very same air sample, offering an early warning system that can trigger root cause analysis and corrective action far sooner than waiting on a week-long incubation period allows.
Cleanroom Design as an Investment in Future Compliance
Sound cleanroom design and rigorous environmental monitoring work hand in hand: one creates the controlled space, the other proves it is performing as intended. As Annex 1 continues to push the industry toward rapid and alternative methods, real-time monitoring solutions promise simpler root cause analysis, fewer operator interventions, lower contamination risk and faster batch release. For manufacturers weighing up their next investment in cleanroom design, building in the flexibility to adopt these emerging monitoring technologies is likely to pay dividends as regulatory expectations continue to evolve.
To discuss aseptic processing and the key issues facing the industry, connect with solution providers and network with delegates,, attend the 6th Aseptic BioPharma Processing Summit, taking place September 22-23, 2026, in Vienna, Austria.
For more information, click here or email us at info@innovatrix.eu for the event agenda. Visit our LinkedIn to stay up to date on our latest speaker announcements and event news
